Mayzent
Named-patient access overview. Mayzent is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Mayzent (siponimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator approved by the US Food and Drug Administration in March 2019 for relapsing forms of multiple sclerosis, with the labeled indication that specifically includes active secondary progressive multiple sclerosis (SPMS). The manufacturer is approximately Novartis. Siponimod is one of a small number of disease-modifying therapies with evidence specifically in the active SPMS population, where treatment options have historically been narrower than in relapsing-remitting MS.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Mayzent
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Mayzent is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Mayzent in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Mayzent
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.